Investment in rare disease biotechs is picking up in the U.S. following the renewal of FDA's Priority Review Voucher (PRV) program, according to SynaptixBio. According to VC firm V-Bio, "Reauthorization of FDA's Rare Pediatric Disease Priority Review Voucher (PRV) scheme has restored financial certainty and sparked intense interest from large pharma. "The U.S. dominates because the PRV program creates a highly valuable and, more importantly, tradable asset," he said. "VCs and private equity firms are far more willing to invest in rare disease biotechs simply because they provide a financial return on investment." Without an equivalent to FDA's PRV program, UK rare disease biotech’s will rely heavily on public markets, private investment, or acquisition by larger global pharma to secure capital."